{"id":4416,"date":"2023-03-16T23:15:04","date_gmt":"2023-03-16T22:15:04","guid":{"rendered":"http:\/\/www.aunomdanna.fr\/blog\/?p=4416"},"modified":"2023-03-16T23:17:36","modified_gmt":"2023-03-16T22:17:36","slug":"molecule-pour-ameliorer-les-symptomes-du-syndrome-de-rett","status":"publish","type":"post","link":"https:\/\/www.aunomdanna.fr\/blog\/?p=4416","title":{"rendered":"Mol\u00e9cule pour am\u00e9liorer les sympt\u00f4mes du syndrome de Rett"},"content":{"rendered":"\n<p>Le 10 mars dernier, la FDA (Food and Drugs Administration) a approuv\u00e9 l\u2019utilisation aux Etats-Unis de la Trofin\u00e9tide, une mol\u00e9cule qui vise \u00e0 am\u00e9liorer plusieurs sympt\u00f4mes du syndrome de Rett. Commercialis\u00e9 sous le nom de Daybue\u00ae, il est donc le premier m\u00e9dicament contre le syndrome de Rett et vient d\u2019obtenir un droit de d\u00e9livrance exceptionnel aux Etats-Unis. Il sera disponible sur prescription m\u00e9dicale et de mani\u00e8re tr\u00e8s encadr\u00e9e aux Etats-Unis d\u00e8s avril 2023.<\/p>\n\n\n\n<p>A ce jour, ce m\u00e9dicament n\u2019est pas encore autoris\u00e9 en Europe. Les proc\u00e9dures et les d\u00e9marches pour obtenir une autorisation de mise sur le march\u00e9 en Europe font l\u2019objet d\u2019accords entre les laboratoires am\u00e9ricains et europ\u00e9ens.<\/p>\n\n\n\n<p>L\u2019Association Fran\u00e7aise du Syndrome de Rett ainsi que les membres de son Conseil M\u00e9dical et Scientifique sont mobilis\u00e9s afin de pouvoir suivre les avanc\u00e9es et permettre la prescription en France.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><a href=\"https:\/\/www.aunomdanna.fr\/blog\/wp-content\/uploads\/2023\/03\/fa5f78c088d0b41f6d2e758a21f1f9281beb5ff05355c7a76b2e7cace0d15a9b.png\" rel=\"lightbox[4416]\"><img loading=\"lazy\" decoding=\"async\" width=\"369\" height=\"561\" src=\"https:\/\/www.aunomdanna.fr\/blog\/wp-content\/uploads\/2023\/03\/fa5f78c088d0b41f6d2e758a21f1f9281beb5ff05355c7a76b2e7cace0d15a9b.png\" alt=\"\" class=\"wp-image-4418\" srcset=\"https:\/\/www.aunomdanna.fr\/blog\/wp-content\/uploads\/2023\/03\/fa5f78c088d0b41f6d2e758a21f1f9281beb5ff05355c7a76b2e7cace0d15a9b.png 369w, https:\/\/www.aunomdanna.fr\/blog\/wp-content\/uploads\/2023\/03\/fa5f78c088d0b41f6d2e758a21f1f9281beb5ff05355c7a76b2e7cace0d15a9b-197x300.png 197w\" sizes=\"auto, (max-width: 369px) 100vw, 369px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Le 10 mars dernier, la FDA (Food and Drugs Administration) a approuv\u00e9 l\u2019utilisation aux Etats-Unis de la Trofin\u00e9tide, une mol\u00e9cule qui vise \u00e0 am\u00e9liorer plusieurs sympt\u00f4mes du syndrome de Rett. Commercialis\u00e9 sous le nom de Daybue\u00ae, il est donc le premier m\u00e9dicament contre le syndrome de Rett et vient d\u2019obtenir un droit de d\u00e9livrance exceptionnel&#8230; <\/p>\n<div class=\"link-more\"><a href=\"https:\/\/www.aunomdanna.fr\/blog\/?p=4416\">En savoir plus<\/a><\/div>\n","protected":false},"author":1,"featured_media":4418,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[3],"tags":[],"class_list":["post-4416","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-quotidien"],"jetpack_featured_media_url":"https:\/\/www.aunomdanna.fr\/blog\/wp-content\/uploads\/2023\/03\/fa5f78c088d0b41f6d2e758a21f1f9281beb5ff05355c7a76b2e7cace0d15a9b.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.aunomdanna.fr\/blog\/index.php?rest_route=\/wp\/v2\/posts\/4416","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.aunomdanna.fr\/blog\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.aunomdanna.fr\/blog\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.aunomdanna.fr\/blog\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.aunomdanna.fr\/blog\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4416"}],"version-history":[{"count":2,"href":"https:\/\/www.aunomdanna.fr\/blog\/index.php?rest_route=\/wp\/v2\/posts\/4416\/revisions"}],"predecessor-version":[{"id":4419,"href":"https:\/\/www.aunomdanna.fr\/blog\/index.php?rest_route=\/wp\/v2\/posts\/4416\/revisions\/4419"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.aunomdanna.fr\/blog\/index.php?rest_route=\/wp\/v2\/media\/4418"}],"wp:attachment":[{"href":"https:\/\/www.aunomdanna.fr\/blog\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4416"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.aunomdanna.fr\/blog\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4416"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.aunomdanna.fr\/blog\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4416"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}